INM.WAR InventionMed

Healthcare Health Care Equipment & Supplies Warsaw Stock Exchange
0.1105 PLN
Close of Oct 29, 2026
0.0990 0.1460
Market cap
PLN 22.4M
P/E
-
P/B
17.76x
ROE
76.0%
Dividend yield
-
Fundamental score
1.1/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is INM.WAR undervalued?

Graham number

The Graham number of InventionMed cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

InventionMed fundamental analysis

4 of 22 checks passed

ROE 2/2

High return on equity (76.0%), above 20%.

ROA 1/1

Return on assets (2.3%) is above the industry median (-6.0%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share did not grow over the past 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 1/1

Last year's EPS growth (83.0%) is above the industry median (24.1%).

Revenue Growth 2/2

Revenue grew 820.5% a year over the past 3 years.

Short-term Liquidity 0/1

Current assets do not cover short-term liabilities.

Long-term Liabilities 0/1

Current assets do not cover long-term liabilities.

Debt to Equity 0/2

Debt to equity cannot be calculated: debt is not reported or equity is negative.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Debt Coverage 0/1

Debt is not reported.

Interest Coverage 0/1

EBIT is 1.7x against interest expense, below 5x.

PE vs Market 0/1

PE is negative or not available.

PE vs Industry 0/1

PE is negative or not available.

PBV 0/1

Price to book (17.8x) is above the industry median (3.4x).

Graham Number 0/1

Graham number needs positive earnings and book value.

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

InventionMed stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About InventionMed

InventionMed S.A. focuses on the development of medical simulators based on Virtual Realty technology for use in education in esthetic and clinical dermatology. The company flagship project is TutorDerm, a simulator and an application that lets users perform actions necessary to treat specific dermatological diseases. It also offers double immersion, and Virtual Syringe, a training equipment for specialists in clinical and aesthetic dermatology. In addition, the company prov…

Full company profile